Treatment Strategy for Distant Synchronous Metastatic Head and Neck Squamous Cell Carcinoma
- 51 Downloads
Purpose of Review
Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm.
With the rise of novel therapeutic techniques and medications, many treatment options for both locoregional and distant metastatic disease have become available. The evolving paradigm of metastatic disease now integrates the concept of oligometastatic disease. On top of systemic treatments, patients with low metastatic burden can benefit from curative approaches such as local therapies (surgery, radiotherapy) directed to either primary tumour and distant metastasis. However, data integrating these considerations in the management of metastatic HNSCC is still lacking.
Based on this algorithm, we can provide a tailored treatment to each patient with synchronous metastatic HNSCC, according to their age, general condition and metastatic burden.
KeywordsSquamous cell cancer Head and neck cancer Metastases Chemotherapy Radiotherapy Treatment algorithm
Compliance with Ethical Standards
Conflict of Interest
Eliane Tang, Lucien Lahmi, Nicolas Meillan, Gianandrea Pietta, Sébastien Albert, and Philippe Maingon declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Garavello W, Ciardo A, Spreafico R, Gaini RM. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Neck Surg. 2006;132:762–6.Google Scholar
- 10.Huang SH, Perez-Ordonez B, Liu F-F, Waldron J, Ringash J, Irish J, et al. Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol. 2012;82:276–83.Google Scholar
- 12.Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.Google Scholar
- 16.Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP, et al. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. Cancer Screen Still Work Prog. 2017;44:13–23.Google Scholar
- 17.Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol. 2018;mdy040–mdy040.Google Scholar
- 18.Pfister DG, Foote RL, Gilbert J, Gillison ML, Ridge JA, Rocco J. NCCN Guidelines Index Table of Contents Discussion 2018;227.Google Scholar
- 21.Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 17:956–65.PubMedGoogle Scholar
- 22.Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol. 2017;18:1104–15.PubMedPubMedCentralGoogle Scholar
- 28.Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience. Radiat Oncol. 2017;12.Google Scholar
- 29.Bhattacharya IS, Hoskin PJ. Stereotactic body radiotherapy for spinal and bone metastases. Clin Oncol. 2015;27:298–306.Google Scholar
- 30.Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1452 patients and development of a prognostic model. Trans Meet Am Surg Assoc. 2006;124:189–200.Google Scholar
- 36.Patel RA, Bell JB, Kim T, Agulnik M, Chandler JP, Mittal BB, et al. Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. J Neuro-Oncol. 2017;134:197–203.Google Scholar
- 38.•• Kabarriti R, Baliga S, Ohri N, Guha C, Kalnicki S, Garg MK. Radiation therapy for patients with newly diagnosed metastatic head and neck squamous cell carcinoma. Head Neck. 2018;41(1):130–8 First clinical study to demonstrate a survival benefit for the use of radiotherapy in the initial management of metastatic HNSCC. PubMedGoogle Scholar
- 39.• Patel TD, Marchiano E, Chin OY, Kilic S, Eloy JA, Baredes S, et al. Utility of surgery/radiotherapy in distant metastatic head and neck squamous cell carcinoma: a population-based approach. Otolaryngol-Head Neck Surg. 2016;154:868–74 Study reporting longer survival in metastatic HNSCC patients treated with radiotherapy and/or surgery compared to patients who did not undergo any therapy. PubMedGoogle Scholar
- 40.•• Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, et al. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: an analysis of the National Cancer Data Base: local treatment in metastatic HNSCC. Cancer. 2017;123:4583–93 Study reporting an association between prolonged OS and the addition of high-intensity local treatment (radiotherapy delivered at curative dose or surgery) to systemic therapy in metastatic HNSCC patients. PubMedPubMedCentralGoogle Scholar
- 44.Mertens C, Le Caer H, Ortholan C, Blot E, Even C, Rousselot H, et al. The ELAN-ONCOVAL (ELderly heAd and neck cancer-oncology eValuation) study: evaluation of the feasibility of a suited geriatric assessment for use by oncologists to classify patients as fit or unfit. Ann Oncol. 2017;28.Google Scholar
- 46.Leclerc M, Maingon P, Hamoir M, Dalban C, Calais G, Nuyts S, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. Radiother Oncol. 2013;106:333–40.PubMedGoogle Scholar
- 47.Vermorken JB, Psyrri A, Mesía R, Peyrade F, Beier F, de Blas B, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol. 2014;25:801–7.PubMedPubMedCentralGoogle Scholar
- 48.Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697–710.PubMedGoogle Scholar
- 49.Mehra R, Egloff AM, Li S, Yang D, Wang L, Zhu F, et al. Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol. 2013;31:6006.Google Scholar